Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com..
BACKGROUND AND AIMS: Patients with acute myeloid leukaemia (AML) suffer from severe myocardial injury during daunorubicin (DNR)-based chemotherapy and are at high risk of cardiac mortality. The crosstalk between tumour cells and cardiomyocytes might play an important role in chemotherapy-related cardiotoxicity, but this has yet to be demonstrated. This study aimed to identify its underlying mechanism and explore potential therapeutic targets.
METHODS: Cardiac tissues were harvested from an AML patient after DNR-based chemotherapy and were subjected to single-nucleus RNA sequencing. Cardiac metabolism and function were evaluated in AML mice after DNR treatment by using positron emission tomography, magnetic resonance imaging, and stable-isotope tracing metabolomics. Plasma cytokines were screened in AML mice after DNR treatment. Genetically modified mice and cell lines were used to validate the central role of the identified cytokine and explore its downstream effectors.
RESULTS: In the AML patient, disruption of cardiac metabolic homeostasis was associated with heart dysfunction after DNR-based chemotherapy. In AML mice, cardiac fatty acid utilization was attenuated, resulting in cardiac dysfunction after DNR treatment, but these phenotypes were not observed in similarly treated tumour-free mice. Furthermore, tumour cell-derived interleukin (IL)-1α was identified as a primary factor leading to DNR-induced cardiac dysfunction and administration of an anti-IL-1α neutralizing antibody could improve cardiac functions in AML mice after DNR treatment.
CONCLUSIONS: This study revealed that crosstalk between tumour cells and cardiomyocytes during chemotherapy could disturb cardiac energy metabolism and impair heart function. IL-1α neutralizing antibody treatment is a promising strategy for alleviating chemotherapy-induced cardiotoxicity in AML patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
European heart journal - (2024) vom: 12. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Xingliang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute myeloid leukaemia |
|---|
| Anmerkungen: |
Date Revised 12.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/eurheartj/ehae188 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370968697 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370968697 | ||
| 003 | DE-627 | ||
| 005 | 20240412234220.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurheartj/ehae188 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM370968697 | ||
| 035 | |a (NLM)38607560 | ||
| 035 | |a (PII)ehae188 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Xingliang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. | ||
| 520 | |a BACKGROUND AND AIMS: Patients with acute myeloid leukaemia (AML) suffer from severe myocardial injury during daunorubicin (DNR)-based chemotherapy and are at high risk of cardiac mortality. The crosstalk between tumour cells and cardiomyocytes might play an important role in chemotherapy-related cardiotoxicity, but this has yet to be demonstrated. This study aimed to identify its underlying mechanism and explore potential therapeutic targets | ||
| 520 | |a METHODS: Cardiac tissues were harvested from an AML patient after DNR-based chemotherapy and were subjected to single-nucleus RNA sequencing. Cardiac metabolism and function were evaluated in AML mice after DNR treatment by using positron emission tomography, magnetic resonance imaging, and stable-isotope tracing metabolomics. Plasma cytokines were screened in AML mice after DNR treatment. Genetically modified mice and cell lines were used to validate the central role of the identified cytokine and explore its downstream effectors | ||
| 520 | |a RESULTS: In the AML patient, disruption of cardiac metabolic homeostasis was associated with heart dysfunction after DNR-based chemotherapy. In AML mice, cardiac fatty acid utilization was attenuated, resulting in cardiac dysfunction after DNR treatment, but these phenotypes were not observed in similarly treated tumour-free mice. Furthermore, tumour cell-derived interleukin (IL)-1α was identified as a primary factor leading to DNR-induced cardiac dysfunction and administration of an anti-IL-1α neutralizing antibody could improve cardiac functions in AML mice after DNR treatment | ||
| 520 | |a CONCLUSIONS: This study revealed that crosstalk between tumour cells and cardiomyocytes during chemotherapy could disturb cardiac energy metabolism and impair heart function. IL-1α neutralizing antibody treatment is a promising strategy for alleviating chemotherapy-induced cardiotoxicity in AML patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute myeloid leukaemia | |
| 650 | 4 | |a Cardiac energy metabolism | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Interleukin 1 alpha | |
| 700 | 1 | |a Liu, Yiwei |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lijun |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Wenting |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Bei |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Yifan |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Chenyu |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Zihao |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Liwei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tianyu |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Lijun |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Caiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Shuhong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal |d 1983 |g (2024) vom: 12. Apr. |w (DE-627)NLM012617253 |x 1522-9645 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/eurheartj/ehae188 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 04 | ||